Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclerion Therapeutics, Inc. - Common Stock (NQ: CYCN )

3.120 +0.090 (+2.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat 
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Regina Graul, Ph.D., Promoted to Chief Executive Officer
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Appoints Regina Graul, Ph.D., as President
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Announces Reverse Stock Split
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
Renowned neuroscience leader to further long-term clinical research strategy and external collaborations 
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.